October 15, 2024

New Member: Welcome in our cluster to Daiichi Sankyo Europe GmbH

New Member: Welcome in our cluster to Daiichi Sankyo Europe GmbH
Go back

Daiichi Sankyo’s European roots date back to the 1980s with branches in Düsseldorf. In 1990, Sankyo acquired Luitpold-Werke, a German pharmaceutical company, expanding operations to Pfaffenhofen, Germany, and Altkirch, France. In 2006, Daiichi and Sankyo merged, with European headquarters in Munich. Now present in 13 countries, Daiichi Sankyo employs over 2,000 people, making it one of Europe’s largest Japanese pharmaceutical companies. It develops and markets treatments for hypertension, dyslipidemia, infections, cardiovascular diseases, and thrombotic disorders.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
New paper by BioThrust: 𝗡𝗞-𝟵𝟮 𝗰𝗲𝗹𝗹 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗯𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸 𝗮𝘁 𝟮𝗟 𝘀𝗰𝗮𝗹𝗲!

New paper by BioThrust: 𝗡𝗞-𝟵𝟮 𝗰𝗲𝗹𝗹 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗯𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸 𝗮𝘁 𝟮𝗟 𝘀𝗰𝗮𝗹𝗲!

The bioprocess experts from BioThrust Yasemin van Heuvel, Valentin von Werz and the group of Oliver Spadiut at Technische Universität Wien and the team at SimVantage released this publication on NK-92 cell manufacturing. The team collaborated to compare our ComfyCell bioreactor with a conventional pitched-blade stirred-tank bioreactor (2 L scale). While both systems supported comparable […]

read more
Paul Martini Prize for Professor Alwin Krämer

Paul Martini Prize for Professor Alwin Krämer

On April 20, 2026, Prof. Alwin Krämer, MD, of the Heidelberg Medical Faculty at Heidelberg University, who works at the German Cancer Research Center (DKFZ) and Heidelberg University Hospital, received the 2026 Paul Martini Prize. The prize was awarded for groundbreaking improvements in treatment for some patients with metastases from an unknown primary tumor, known […]

read more
3D-Printed Tissue Substitute

3D-Printed Tissue Substitute

A novel developed biomimetic tissue substitute combines precisely tunable mechanical properties with biological functionality and is now ready for applications in medical technology. The material was developed in the »PolyKARD« project by the Fraunhofer Institute for Applied Polymer Research IAP and the NMI Natural and Medical Sciences Institute. From April 20 to 24, 2026, the […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp